This manuscript describes an unprecedented and efficient synthesis of a new DPP scaffold, 2,5-dibutyl-3,6-dimethyl-1 H,2 H,4 H,5 H-pyrrolo[3,4- c]pyrrole-1,4-dione (DMDPP), containing methyl groups at the 3,6-positions as a precursor to preparing 3,6-divinyl-substituted DPP compounds. Subsequently, following the synthesis of DMDPP, we performed an efficient and mild C-H functionalization of the methyl groups with a variety of aromatic aldehydes to synthesize the first examples of 3,6-divinyl-substituted DPP compounds in moderate to good yields.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.orglett.9b00019DOI Listing

Publication Analysis

Top Keywords

25-dibutyl-36-dimethyl-1 h-pyrrolo[34-
8
h-pyrrolo[34- c]pyrrole-14-dione
8
methyl groups
8
36-divinyl-substituted dpp
8
dpp compounds
8
synthesis 25-dibutyl-36-dimethyl-1
4
c]pyrrole-14-dione a diketopyrrolopyrrole
4
a diketopyrrolopyrrole scaffold
4
scaffold formation
4
formation alkenyldiketopyrrolopyrrole
4

Similar Publications

AT-IAP (1-{6-[(4-fluorophenyl)methyl]-3,3-dimethyl-1H,2H,3H-pyrrolo[3,2-b]pyridin-1-yl}-2-[(2R,5R)-5-methyl-2-{[(3R)-3-methylmorpholin-4-yl]methyl}piperazin-1-yl]ethan-1-one) was identified as a novel potent non-alanine small molecule dual inhibitor of cIAP1/XIAP protein. AT-IAP was assessed in preclinical species, demonstrating favorable bioavailability in rodent species and oral efficacy at 30 mg/kg in MDA-MB-231 mouse xenograft models. The major metabolic route of AT-IAP was identified to be CYP3A driven, resulting in low oral exposure in non-human primate (NHP) studies, given the comparatively high expression of equivalent CYP3A.

View Article and Find Full Text PDF

The incorporation of the fluorine motif is a strategy widely applied in drug design for modulating the activity, physicochemical parameters, and metabolic stability of chemical compounds. In this study, we attempted to reduce the affinity for ether-à-go-go-related gene (hERG) channel by introducing fluorine atoms in a group of 1H-pyrrolo[3,2-c]quinolines that are capable of inhibiting monoamine oxidase type B (MAO-B). A series of structural modifications guided by in vitro evaluation of MAO-B inhibition and antitargeting for hERG channels were performed, which led to the identification of 1-(3-chlorobenzyl)-4-(4,4-difluoropiperidin-1-yl)-1H-pyrrolo[3,2-c]quinoline (26).

View Article and Find Full Text PDF
Article Synopsis
  • JAK1 is essential for inflammatory and autoimmune responses, making its inhibition a potential treatment for various diseases.
  • Researchers designed a new JAK1-selective inhibitor by analyzing how current inhibitors bind to JAK isoforms and created a potent compound called () with high selectivity for JAK1.
  • The compound effectively reduces liver fibrosis by inhibiting the proliferation and migration of liver cells activated by TGF-β at low concentrations.
View Article and Find Full Text PDF

Akt, a crucial protein involved in a variety of signaling pathways in cancer, acts as an important regulator of survival in hepatocellular carcinoma (HCC), and provides curative option for the related drugs development. We have found an active phenanthroindolizidine alkaloid, (13aR,14R)-9,11,12,13,13a,14-hexahydro-3,6,7-trimethoxydibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol (HTBPI), is a promising Akt inhibitor effective in the suppression of HCC cells proliferation through stimulating apoptotic and autophagic capability in vivo and in vitro. Treatment of HTBPI combined with a classical autophagy-lysosomal inhibitor (bafilomycin A1), could enhance stimulation effects of apoptosis on HCC cell lines.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!